Provides antiretroviral susceptibility information for protease inhibitors (PI), reverse transcriptase inhibitors (NRTI, NNRTI), and integrase inhibitors (INT). Intended for patients with viral load >500 copies/mL.
Massively Parallel Sequencing
New York DOH Approval Status
Lavender (EDTA), pink (K2 EDTA), or plasma preparation tube.
Separate plasma from cells within 24 hours. Transfer 3.0 mL plasma to an ARUP Standard Transport Tube. (Min: 2.5 mL)
Serum. Heparinized specimens.
Please submit most recent viral load and test date, if available.
After separation from cells: Ambient: 24 hours; Refrigerated: 72 hours; Frozen: 3 months
This assay predicts HIV-1 resistance to protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and integrase inhibitors. The protease gene, integrase gene and the reverse transcriptase gene of the viral genome are sequenced using Next Generation Sequencing. Drug resistance is assigned using the Stanford hivdb database.
This test should be used in conjunction with clinical presentation and other laboratory markers. A patient's response to therapy depends on multiple factors, including patient adherence, percentage of resistant virus population, dosing, and drug pharmacology issues.
This test detects populations down to 10 percent of the total population which may account for resistance interpretation differences between methods. Some insertions or deletions may be difficult to detect using this software.
This test was developed, and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
This test may be unsuccessful if the plasma HIV-1 RNA viral load is less than 500 copies per mL of plasma.
87900; 87901; 87906
|Component Test Code*||Component Chart Name||LOINC|
|3003854||HIV-1 Drug Resistance by NGS||80689-3|
|3003855||EER HIV-1 Drug Resistance by NGS||11502-2|
- HIV Drug Resistance
- HIV Genotype
- HIV Integrase
- HIV1 Genotype
- HIV1 Genotyping
- HIV1 Protease and Reverse Transcriptase Genotype
- HIV1 Protease and Reverse Transcriptase Genotyping
- HIV1 Protease and Reverse Transcriptase Sequencing
- HIV1 Protease Genotyping
- HIV1 Reverse Transcriptase Genotyping
- HIV1 Sequencing